An accurate assessment of tumor spread with FAP-specific PET and radiotherapy devices that can perform PET is especially promising for tumors of the upper gastrointestinal tract and the liver where conventional contrast-enhanced CT and FDG PET have several limitations and the variable positions of the organs in relation to one another often require substantial safety margins. This evidence concerns the gene FAP and neoplasm.